REGENXBIO Inc.
Developing AAV gene therapies for retinal, metabolic, and neurodegenerative diseases.
RGNX | NDAQ
Overview
Corporate Details
- ISIN(s):
- US75901B1070
- LEI:
- Country:
- United States of America
- Address:
- 9804 MEDICAL CENTER DRIVE, 20850 ROCKVILLE
- Website:
- https://regenxbio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
REGENXBIO Inc. is a clinical-stage biotechnology company dedicated to improving lives through the curative potential of gene therapy. The company's core is its proprietary NAV® Technology Platform, which utilizes adeno-associated virus (AAV) vectors to deliver one-time treatments for genetic disorders. REGENXBIO develops and commercializes a pipeline of gene therapy product candidates targeting retinal, metabolic, and neurodegenerative diseases. The company supports its robust clinical programs with in-house, commercial-ready manufacturing capabilities, aiming to provide transformative therapies for patients with both common and rare conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all REGENXBIO Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for REGENXBIO Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for REGENXBIO Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
